Kymera Therapeutics (KYMR) CEO exercises 3,118 stock options reported

Rhea-AI Filing Summary

Kymera Therapeutics Chief Executive Officer Nello Mainolfi reported an option exercise involving company stock. On January 5, 2026, he exercised a stock option to acquire 3,118 shares of Kymera Therapeutics common stock at an exercise price of $32.07 per share, reflected as an option exercise (code M). Following this transaction, he directly holds 666,195 shares of common stock and 446,882 stock options in total.

The option exercised relates to a grant whose underlying shares vest in 36 equal monthly installments starting on March 1, 2023, and the vesting continues only if he remains employed through each vesting date. This filing shows a routine equity compensation transaction by Kymera Therapeutics’ CEO, combining ongoing vesting with a partial option exercise.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mainolfi Nello

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		M		3,118	A	$32.07	666,195	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$32.07	01/05/2026		M			3,118	(1)	03/01/2033	Common Stock	3,118	$0	446,882	D

Explanation of Responses:

1. The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.

	/s/ Bruce Jacobs, as Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kymera Therapeutics (KYMR) report for its CEO?

Kymera Therapeutics reported that its Chief Executive Officer, Nello Mainolfi, exercised a stock option on January 5, 2026. He converted 3,118 stock options into 3,118 shares of common stock through an option exercise labeled with transaction code M.

How many Kymera Therapeutics (KYMR) shares does the CEO own after this Form 4 transaction?

After the reported transaction, CEO Nello Mainolfi directly holds 666,195 shares of Kymera Therapeutics common stock. He also holds 446,882 stock options following the option exercise reported on this Form 4.

What was the exercise price for the Kymera Therapeutics (KYMR) stock options exercised?

The exercised stock option had an exercise price of $32.07 per share. On January 5, 2026, 3,118 options at this price were exercised into an equal number of Kymera Therapeutics common shares.

How do the CEO’s Kymera Therapeutics (KYMR) stock options vest?

The stock options underlying this transaction vest in 36 equal monthly installments starting on March 1, 2023. Vesting is subject to the CEO’s continued employment through each monthly vesting date.

Is the Kymera Therapeutics (KYMR) CEO both a director and an officer?

Yes. The reporting person, Nello Mainolfi, is identified as both a Director and an Officer, with the title Chief Executive Officer of Kymera Therapeutics.

Was the Kymera Therapeutics (KYMR) CEO’s transaction reported as direct or indirect ownership?

The Form 4 shows the CEO’s holdings as direct ownership (D) for both the 666,195 shares of common stock and the 446,882 stock options following the reported transaction.